U.S. Meningococcal Vaccines Market Size & Outlook, 2026-2033
Global Market
Related Markets
U.S. meningococcal vaccines market highlights
- The U.S. meningococcal vaccines market generated a revenue of USD 2,028.9 million in 2025 and is expected to reach USD 2,652.8 million by 2033.
- The U.S. market is expected to grow at a CAGR of 3% from 2026 to 2033.
- In terms of segment, menveo was the largest revenue generating brand in 2025.
- Nimenrix is the most lucrative brand segment registering the fastest growth during the forecast period.
Meningococcal vaccines market data book summary
| Market revenue in 2025 | USD 2,028.9 million |
| Market revenue in 2033 | USD 2,652.8 million |
| Growth rate | 3% (CAGR from 2026 to 2033) |
| Largest segment | Menveo |
| Fastest growing segment | Nimenrix |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Menactra, Menveo, Nimenrix, Trumenba, Bexsero |
| Key market players worldwide | Pfizer Inc, Sanofi SA, GSK PLC, Merck & Co Inc, Serum Institute of India Pvt. Ltd., Walvax Biotechnology |
Other key industry trends
- In terms of revenue, U.S. accounted for 50.0% of the global meningococcal vaccines market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. meningococcal vaccines market is projected to lead the regional market in terms of revenue in 2033.
- Mexico is the fastest growing regional market in North America and is projected to reach USD 75.0 million by 2033.
The U.S. dominated the meningococcal vaccine market in 2021 and is projected to continue its dominance over the forecast period owing to presence of key players & favorable reimbursement policies. For instance, CMS provides contract prices for certain large city immunization projects, certain current & former U.S. territories, and state health departments.
Contract prices are lower than private sector prices, which are reported by manufacturers. In addition, rising awareness initiatives undertaken by various organizations, such as Meningitis B Action Project that encourage healthcare providers and young adults to discuss about the vaccine with their families, to create awareness in colleges, campus, & schools drive market growth.
Favorable regulatory scenarios for manufacturers, such as Breakthrough Therapy Designation (BTD) & Fast Track Designation, are likely to boost market growth. For instance, in February 2018, GlaxoSmithKline plc received BTD from the U.S. FDA for Bexsero to prevent Invasive Meningococcal Disease (IMD) caused by serogroup B in children aged 2 to 10.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Meningococcal Vaccines Market Scope
Meningococcal Vaccines Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| GSK PLC | View profile | 70,200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | www.gsk.com |
| Serum Institute of India Pvt. Ltd. | View profile | 1001-5000 | Pune, Maharashtra, India, Asia | www.seruminstitute.com/ |
| Walvax Biotechnology | View profile | 11-50 | Kunming, Yunnan, China, Asia | www.walvax.com |
U.S. Meningococcal Vaccines Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Meningococcal Vaccines Market Outlook will help companies and investors design strategic landscapes.
Menveo was the largest segment with a revenue share of 31.74% in 2025.
Horizon Databook has segmented the U.S. meningococcal vaccines market based on menactra, menveo, nimenrix, trumenba, bexsero covering the revenue growth of each sub-segment from 2021 to 2033.
The U.S. dominated the meningococcal vaccine market in 2021 and is projected to continue its dominance over the forecast period owing to presence of key players & favorable reimbursement policies. For instance, CMS provides contract prices for certain large city immunization projects, certain current & former U.S. territories, and state health departments.
Contract prices are lower than private sector prices, which are reported by manufacturers. In addition, rising awareness initiatives undertaken by various organizations, such as Meningitis B Action Project that encourage healthcare providers and young adults to discuss about the vaccine with their families, to create awareness in colleges, campus, & schools drive market growth.
Favorable regulatory scenarios for manufacturers, such as Breakthrough Therapy Designation (BTD) & Fast Track Designation, are likely to boost market growth. For instance, in February 2018, GlaxoSmithKline plc received BTD from the U.S. FDA for Bexsero to prevent Invasive Meningococcal Disease (IMD) caused by serogroup B in children aged 2 to 10.
- U.S. Meningococcal Vaccines Market Brand Outlook (Revenue, USD Million , 2021-2033)
- Menactra
- Menveo
- Nimenrix
- Trumenba
- Bexsero
- Others
- U.S. Meningococcal Vaccines Market Serotype Outlook (Revenue, USD Million , 2021-2033)
- A
- B
- C
- W-135
- Y
- U.S. Meningococcal Vaccines Market Age Group Outlook (Revenue, USD Million , 2021-2033)
- Infants (0 to 2 years)
- Children and Adults (2 years and above)
- U.S. Meningococcal Vaccines Market Sales Channel Outlook (Revenue, USD Million , 2021-2033)
- Private
- Public
- U.S. Meningococcal Vaccines Market Type Outlook (Revenue, USD Million , 2021-2033)
- Bivalent
- Quadrivalent
- Others
Reasons to subscribe to Meningococcal Vaccines Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Meningococcal Vaccines Market Outlook databook
- Our clientele includes a mix of Meningococcal Vaccines Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. Meningococcal Vaccines Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.S. Meningococcal Vaccines Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
U.S. Meningococcal Vaccines Market, 2021-2033 (US$M)
US Brand - Meningococcal Vaccines Market Statistics, 2025 - 2033 (US$M)
